Sponsors/CROs

Our principal investigators Dr. Ahmed and Dr. Levinson have completed more than 200 clinical trials, phase I, II, III and IV in many therapeutic areas such as Type 2 Diabetes, Cardiovascular Disease, Obesity, Hyperlipidemia, Hypertension, Chronic Kidney Disease.

Dr. Ahmed and Dr. Levinson have together published more than 81 publications in many reputable journals. Below are a few links to their publications.

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee

Our Global Presence from USA to JAPAN

  • Abbott
  • AbbVie
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • BioDelivery Sciences Intl.
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company
  • Eli Lilly and Company
  • Esperion Therapeutics
  • Genentech
  • Gilead
  • GlaskoSmithKline
  • Hisamitsu Pharmaceutical Co.
  • Hoffmann-LaRoche
  • Janssen
  • Johnson and Johnson
  • Kowa Pharmaceuticals America
  • MannKind Corporation
  • Merck
  • Mylan
  • Novartis
  • Novo Nordisk
  • Orexigen Therapeutics
  • Pfizer
  • Purdue Pharma
  • Quantum Genomics
  • Regeneron Pharmaceuticals
  • Roche
  • Samumed
  • Sanofi
  • Semnur
  • Sucampo Pharmaceuticals
  • Takeda
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • Theracos

Listed below are the compounds that Dr. Ahmed and Dr. Levinson have worked on as Principal Investigators.

  • Adalimumab
  • ALN-PCSSC
  • Alogliptin
  • Alosteron
  • Amlodipine
  • Androgel
  • ASP1941
  • Atrasentan
  • Bardoxolone Methyl
  • Bexagliflizin
  • BI 695500
  • BI 695501
  • BMP-7
  • Bococizumab
  • Calcifediol
  • Canagliflozin Choline
  • Fenofibrate
  • Clonidine HCl
  • Tpical Gel 0.1%
  • CTP-499
  • Dapagliflozin
  • Darbepoetin
  • Alfa Diacerein
  • Diacerein
  • Dutogliptin
  • Elagolix
  • Empagliflozin
  • Epotein Alfa
  • Etanercept/Enbr
  • Evolocumab
  • Exenatide
  • Fasinumab
  • Fulranumab
  • GSK189075
  • GSK3196165
  • HKT-500
  • Hydrocodone
  • Extended- release Insulin
  • Detemir Insulin
  • Insulin Glargine/Lixisen atide (LixiLan)
  • JTT-851
  • Linaclotide
  • Linagliptin el
  • Liraglutide
  • Lixisenatide
  • Lubiprostone
  • MOA-728
  • Mylan Insulin Glargine
  • Naltrexone SR/Bupropion SR
  • Nebivolol
  • Oravescent
  • Fentanyl Citrate
  • Oxycodone/Nal oxone
  • Peginesatide
  • Pemafibrate
  • Perindopril
  • Pioglitazone HCl
  • PT003
  • PT009
  • PT010
  • QGC001
  • Regadenoson
  • Repaglinide/Metf ormin
  • Rituximab
  • RO6807952
  • Roxadustat
  • SAR425899
  • Semaglutide
  • SM04690
  • Sotagliflozin
  • TAK-875
  • Tanezumab
  • Tapentadol
  • Ticagrelor
  • Tocilizumab
  • Tujeo (Insuline Glargine 300U/L)
  • Valsartan

For more information on our research site or Sponsor / CRO inquiries, please contact: 

Nusrat Deen
Director of Clinical Research
Phone: (312) 823-6800
Email: ndeen@apexmedicalresearch.com